Stock Research for GALT


Featured Broker: Ally Invest

Get the due diligence for another stock.


GALT Stock Chart & Research Data

The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GALT Due diligence Resources & Stock Charts

The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GALT Detailed Price Forecast - CNN Money CNN View GALT Detailed Summary - Google Finance
Yahoo View GALT Detailed Summary - Yahoo! Finance Zacks View GALT Stock Research & Analysis -

Stock Analysis

TradeIdeas View GALT Trends & Analysis - Trade-Ideas Barrons View GALT Major Holders - Barrons
NASDAQ View GALT Call Transcripts - NASDAQ Seeking View GALT Breaking News & Analysis - Seeking Alpha
Spotlight View GALT Annual Report - OTC Report View GALT OTC Short Report -
TradeKing View GALT Fundamentals - TradeKing Charts View GALT SEC Filings - Bar Chart
WSJ View Historical Prices for GALT - The WSJ Morningstar View Performance/Total Return for GALT - Morningstar
MarketWatch View the Analyst Estimates for GALT - MarketWatch CNBC View the Earnings History for GALT - CNBC
StockMarketWatch View the GALT Earnings - StockMarketWatch MacroAxis View GALT Buy or Sell Recommendations - MacroAxis
Bullish View the GALT Bullish Patterns - American Bulls Short Pains View GALT Short Pain Metrics -

Social Media Mentions

StockTwits View GALT Stock Mentions - StockTwits PennyStocks View GALT Stock Mentions - PennyStockTweets
Twitter View GALT Stock Mentions - Twitter Invest Hub View GALT Investment Forum News - Investor Hub
Yahoo View GALT Stock Mentions - Yahoo! Message Board Seeking Alpha View GALT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GALT - Insider Cow View Insider Transactions for GALT - Insider Cow
CNBC View GALT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GALT - OTC Markets
Yahoo View Insider Transactions for GALT - Yahoo! Finance NASDAQ View Institutional Holdings for GALT - NASDAQ

Stock Charts

FinViz View GALT Stock Insight & Charts - StockCharts View GALT Investment Charts -
BarChart View GALT Stock Overview & Charts - BarChart Trading View View GALT User Generated Charts - Trading View

Latest Financial News for GALT

Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration Robotics Market Influences — Renewed Outlook, Key Drivers of Growth
Posted on Thursday April 26, 2018

NEW YORK, April 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with Dyskinesia
Posted on Monday April 23, 2018

LONDON, UK / ACCESSWIRE / April 23, 2018 / has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On April 18, 2018, the Company announced positive data from the completed Phase-3 open-label trial, EASE LID 2, assessing GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
Posted on Wednesday April 18, 2018

NORCROSS, Ga., April 18, 2018-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’ s CEO and CMO, ...

Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
Posted on Monday April 16, 2018

NORCROSS, Ga., April 16, 2018-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International ...

Enter a stock symbol to view the stock details.